vs
Side-by-side financial comparison of Core Laboratories Inc. (CLB) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Core Laboratories Inc. is the larger business by last-quarter revenue ($121.8M vs $86.8M, roughly 1.4× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -1.4%). Core Laboratories Inc. produced more free cash flow last quarter ($517.0K vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -3.4%).
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CLB vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $121.8M | $86.8M |
| Net Profit | $5.1M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 1.5% | -84.7% |
| Net Margin | 4.2% | — |
| Revenue YoY | -1.4% | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $121.8M | — | ||
| Q4 25 | $138.3M | $86.8M | ||
| Q3 25 | $134.5M | $67.5M | ||
| Q2 25 | $130.2M | $60.0M | ||
| Q1 25 | $123.6M | $49.3M | ||
| Q4 24 | $129.2M | $73.7M | ||
| Q3 24 | $134.4M | $58.6M | ||
| Q2 24 | $130.6M | $31.1M |
| Q1 26 | $5.1M | — | ||
| Q4 25 | $4.9M | — | ||
| Q3 25 | $14.2M | $-91.3M | ||
| Q2 25 | $10.6M | $-111.7M | ||
| Q1 25 | $-154.0K | $-116.2M | ||
| Q4 24 | $7.4M | — | ||
| Q3 24 | $11.7M | $-83.5M | ||
| Q2 24 | $9.0M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | 20.8% | 67.4% | ||
| Q3 25 | 22.0% | 43.0% | ||
| Q2 25 | 20.3% | 5.5% | ||
| Q1 25 | 19.5% | -0.8% | ||
| Q4 24 | 17.8% | 68.7% | ||
| Q3 24 | 20.5% | 46.2% | ||
| Q2 24 | 21.2% | -0.8% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 11.5% | -84.7% | ||
| Q3 25 | 15.6% | -140.7% | ||
| Q2 25 | 11.7% | -189.8% | ||
| Q1 25 | 3.6% | -245.8% | ||
| Q4 24 | 11.0% | -117.5% | ||
| Q3 24 | 14.7% | -152.1% | ||
| Q2 24 | 12.3% | -327.6% |
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 10.6% | -135.3% | ||
| Q2 25 | 8.2% | -186.2% | ||
| Q1 25 | -0.1% | -235.5% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 8.7% | -142.7% | ||
| Q2 24 | 6.9% | -312.2% |
| Q1 26 | $0.11 | — | ||
| Q4 25 | $0.11 | — | ||
| Q3 25 | $0.30 | — | ||
| Q2 25 | $0.22 | $-0.33 | ||
| Q1 25 | $0.00 | $-0.36 | ||
| Q4 24 | $0.15 | $-0.24 | ||
| Q3 24 | $0.25 | $-0.28 | ||
| Q2 24 | $0.19 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.8M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $275.1M | $698.6M |
| Total Assets | $587.7M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $22.8M | — | ||
| Q4 25 | $22.7M | $297.0M | ||
| Q3 25 | $25.6M | $300.8M | ||
| Q2 25 | $31.2M | $301.2M | ||
| Q1 25 | $22.1M | $359.7M | ||
| Q4 24 | $19.2M | $323.8M | ||
| Q3 24 | $21.5M | $397.5M | ||
| Q2 24 | $17.7M | $412.5M |
| Q1 26 | — | — | ||
| Q4 25 | $110.3M | — | ||
| Q3 25 | $114.1M | — | ||
| Q2 25 | $124.6M | — | ||
| Q1 25 | $124.4M | — | ||
| Q4 24 | $126.1M | — | ||
| Q3 24 | $139.9M | — | ||
| Q2 24 | $147.6M | — |
| Q1 26 | $275.1M | — | ||
| Q4 25 | $266.0M | $698.6M | ||
| Q3 25 | $271.3M | $702.3M | ||
| Q2 25 | $261.3M | $698.5M | ||
| Q1 25 | $253.4M | $767.9M | ||
| Q4 24 | $246.6M | $710.4M | ||
| Q3 24 | $250.7M | $773.5M | ||
| Q2 24 | $240.3M | $768.5M |
| Q1 26 | $587.7M | — | ||
| Q4 25 | $584.0M | $913.2M | ||
| Q3 25 | $591.4M | $904.9M | ||
| Q2 25 | $602.1M | $907.4M | ||
| Q1 25 | $591.5M | $966.7M | ||
| Q4 24 | $585.1M | $910.4M | ||
| Q3 24 | $600.5M | $991.1M | ||
| Q2 24 | $597.8M | $964.3M |
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.56× | — | ||
| Q2 24 | 0.61× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-52.6M |
| Free Cash FlowOCF − Capex | $517.0K | $-61.9M |
| FCF MarginFCF / Revenue | 0.4% | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | 0.77× | — |
| TTM Free Cash FlowTrailing 4 quarters | $22.5M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.0M | — | ||
| Q4 25 | $7.9M | $-52.6M | ||
| Q3 25 | $8.5M | $-78.7M | ||
| Q2 25 | $13.9M | $-67.4M | ||
| Q1 25 | $6.7M | $-103.7M | ||
| Q4 24 | $20.6M | $-73.3M | ||
| Q3 24 | $13.1M | $-59.0M | ||
| Q2 24 | $17.1M | $-98.4M |
| Q1 26 | $517.0K | — | ||
| Q4 25 | $5.0M | $-61.9M | ||
| Q3 25 | $6.5M | $-89.5M | ||
| Q2 25 | $10.4M | $-74.9M | ||
| Q1 25 | $3.9M | $-109.9M | ||
| Q4 24 | $17.4M | $-77.5M | ||
| Q3 24 | $10.4M | $-61.3M | ||
| Q2 24 | $14.3M | $-98.9M |
| Q1 26 | 0.4% | — | ||
| Q4 25 | 3.6% | -71.3% | ||
| Q3 25 | 4.8% | -132.7% | ||
| Q2 25 | 8.0% | -124.9% | ||
| Q1 25 | 3.1% | -222.8% | ||
| Q4 24 | 13.4% | -105.1% | ||
| Q3 24 | 7.7% | -104.6% | ||
| Q2 24 | 10.9% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 10.7% | ||
| Q3 25 | 1.5% | 16.1% | ||
| Q2 25 | 2.7% | 12.4% | ||
| Q1 25 | 2.3% | 12.6% | ||
| Q4 24 | 2.5% | 5.7% | ||
| Q3 24 | 2.0% | 3.9% | ||
| Q2 24 | 2.2% | 1.4% |
| Q1 26 | 0.77× | — | ||
| Q4 25 | 1.61× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.78× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLB
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
